Biomarker study of patients with HER2-negative metastatic breast cancer receiving combination therapy with nivolumab, bevacizumab and paclitaxel as first-line treatment (WJOG9917BTR)

被引：2
|
作者：
Ozaki, Y.
Kitano, S.
Matsumoto, K.
Takahashi, M.
Mukohara, T.
Futamura, M.
Masuda, N.
Tsurutani, J.
Yoshimura, K.
Minami, H.
Takano, T.
机构：
[1] Toranomon Gen Hosp, Tokyo, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Hyogo Canc Ctr, Akashi, Hyogo, Japan
[4] NHO Hokkaido Canc Ctr, Sapporo, Hokkaido, Japan
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Gifu Univ, Gifu, Japan
[7] NHO Osaka Natl Hosp, Osaka, Japan
[8] Kindai Univ, Osaka, Japan
[9] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[10] Kobe Univ, Sch Med, Kobe, Hyogo, Japan
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT1-12-02
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT1-12-02
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Difference of immunological status and response to immune checkpoint inhibitor between recurrent and de novo stage IV HER2-negative breast cancer in NEWBEAT trial (WJOG9917BTR)
    Ozaki, Y.
    Kitano, S.
    Yamashita, M.
    Ikarashi, D.
    Tsurutani, J.
    Iwasa, T.
    Takahashi, M.
    Mukohara, T.
    Masuda, N.
    Futamura, M.
    Minami, H.
    Matsumoto, K.
    Hashimoto, Y. Tanabe
    Kawabata, H.
    Yoshimura, K.
    Takano, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S654 - S654
  • [42] Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer
    Zielinski, Christoph
    Lang, Istvan
    Beslija, Semir
    Kahan, Zsuzsanna
    Inbar, Moshe J.
    Stemmer, Salomon M.
    Anghel, Rodica
    Vrbanec, Damir
    Messinger, Diethelm
    Brodowicz, Thomas
    BRITISH JOURNAL OF CANCER, 2016, 114 (02) : 163 - 170
  • [43] Prolonged (≥1 Year) Exposure to First-Line Bevacizumab Combined with Paclitaxel in Patients with HER2-Negative Metastatic Breast Cancer Treated in a Routine Oncology Practice Study
    Kuemmel, S.
    Schneeweiss, A.
    Foerster, F. G.
    Geberth, M.
    Tesch, H.
    Klare, P.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Schmidt, M.
    CANCER RESEARCH, 2011, 71
  • [44] Efficacy and safety of first-line bevacizumab (Bev) combined with paclitaxel (Pac): An observational study in 786 patients (pts) with HER2-negative metastatic breast cancer (mBC).
    Klare, P.
    Foerster, F. G.
    Geberth, M.
    Schneeweiss, A.
    Tesch, H.
    Kuemmel, S.
    Schumacher, C.
    Hollburg, W.
    Soeling, U.
    Schmidt, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study
    Schneeweiss, Andreas
    Forster, Frank
    Tesch, Hans
    Aktas, Bahriye
    Gluz, Oleg
    Geberth, Matthias
    Hertz-Eichenrode, Martin M.
    Schonegg, Winfried
    Schumacher, Claudia
    Kutscheidt, Andreas
    Kiewitz, Claudia
    Klawitter, Sandra
    Schmidt, Marcus
    ANTICANCER RESEARCH, 2016, 36 (03) : 967 - 974
  • [46] A phase I/II study of docetaxel/epirubicin/bevacizumab (DEB) as first-line therapy for metastatic, HER2-negative breast cancer (MBC).
    Mavroudis, D.
    Boukovinas, I.
    Christophyllakis, C.
    Xenidis, N.
    Papakotoulas, P.
    Malamos, N. A.
    Kakolyris, S.
    Polyzos, A.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Plasma biomarker analysis in patients with HER2-negative locally recurrent or metastatic breast cancer (LR/MBC) treated with first-line bevacizumab (A) and paclitaxel (T) without or with capecitabine (X)
    Lam, Siu W.
    Nota, Nienke M.
    de Groot, Steffen M.
    Jager, Agnes
    Bos, Monique M. E. M.
    Linn, Sabine C.
    van den Bosch, Joan
    Braun, Hans J.
    van der Velden, Ankie M. T.
    Los, Maartje
    Portielje, Johanneke E. A.
    Kroep, Judith R.
    Honkoop, Aafke H.
    Smorenburg, Carolien H.
    Tanis, Bea
    van Riel, Johanna M. G. H.
    Terwogt, Jetske M. Meerum
    den Boer, Marien O.
    Douma, Joep
    Jeurissen, Frank
    Berends, Johan
    van Tinteren, Harm
    Boven, Epie
    CANCER RESEARCH, 2015, 75
  • [48] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
    Beslija, S.
    Brodowicz, T.
    Greil, R.
    Inbar, M. J.
    Kahan, Z.
    Kaufman, B.
    Lang, I.
    Steger, G. G.
    Stemmer, S. M.
    Zielinski, C.
    Zvirbule, Z.
    CANCER RESEARCH, 2011, 71
  • [49] Adding bevacizumab to paclitaxel in the first-line treatment of metastatic breast cancer
    Kevin R. Fox
    Current Oncology Reports, 2009, 11 : 5 - 7
  • [50] Adding Bevacizumab to Paclitaxel in the First-Line Treatment of Metastatic Breast Cancer
    Fox, Kevin R.
    CURRENT ONCOLOGY REPORTS, 2009, 11 (01) : 5 - 6
12345